title: Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer.
abstract: BACKGROUND
  Complete cytoreduction is the most important prognostic factor in ovarian cancer. However, there exist conflicting data on whether the removal of microscopic tumor metastasis in macroscopically unsuspicious retroperitoneal lymph nodes is beneficial.
  
  
  METHODS
  Ovarian cancer tissues and tissues from lymph node metastasis of 30 patients with FIGO IIIC or IV disease undergoing neoadjuvant chemotherapy (NACT) were obtained and assessed using a validated regression score. Histopathological markers, size of largest tumor focus, and overall score were evaluated in lymph node and ovarian tissue. Regression and known prognostic factors were analyzed for influence on survival.
  
  
  RESULTS
  No difference in the overall score between lymph nodes and ovarian tissue was shown, however, single parameters such as fibrosis and pattern of tumor infiltration, were significantly different.
  
  
  CONCLUSIONS
  The pattern of tumor regression in lymph nodes and ovarian tissue are of prognostic value. Lymph node dissection even of unsuspicious nodes should, therefore, be performed.
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany mignon-denise.keyver-paik@ukb.uni-bonn.de.
authors.forename: Mignon-Denise
authors.initials: MD
authors.lastname: Keyver-Paik
authors.affiliation: Department of Anaesthesiology, DRK Kliniken Berlin Westend, Berlin, Germany.
authors.forename: Janne Myriam
authors.initials: JM
authors.lastname: Arden
authors.affiliation: Department of Pathology, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Christine
authors.initials: C
authors.lastname: Lüders
authors.affiliation: Department of Pathology, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Thore
authors.initials: T
authors.lastname: Thiesler
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Alina
authors.initials: A
authors.lastname: Abramian
authors.affiliation: Department for Biostatistics, University of Bonn, Bonn, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Hoeller
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hecking
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Tiyasha Hosne
authors.initials: TH
authors.lastname: Ayub
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Anna
authors.initials: A
authors.lastname: Doeser
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Christina
authors.initials: C
authors.lastname: Kaiser
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology Cologne Bonn, University of Bonn, Bonn, Germany.
authors.forename: Walther
authors.initials: W
authors.lastname: Kuhn
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005355:Fibrosis; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000187:drug effects* / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012187:Retroperitoneal Space; D043823:Taxoids / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D001952:Bridged-Ring Compounds; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D016190:Carboplatin; D000093542:Gemcitabine
keywords: Ovarian cancer; lymph nodes; neoadjuvant chemotherapy; tumor regression